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Ki-67Summary Extrapulmonary neuroendocrine carcinoma (EPNEC) is a heterogeneous and rare group of
high-grade neoplasms occurring in different organs. They usually share a poor prognosis, but diagnostic
and therapeutic options still include several controversial issues, due to the rarity of this condition and to
differences in architecture and cell size, being some cases pure small cell carcinomas, other pure large
cell neuroendocrine carcinomas and some others combined/mixed neuroendocrine carcinomas with a
conventional non-neuroendocrine carcinoma. In addition, the therapeutic strategy varies in different
organs (surgery and/or chemotherapy and/or radiation therapy and/or targeted treatments), and clinicians
and pathologists are asked to interact to reach an accurate classification of every single case, as well as
the most appropriate selection of the treatment options, even considering different time points of each
EPNEC natural history. This overview highlights controversial pathological and clinical issues and
summarizes possible solutions to most of such EPNEC-related problems.
© 2013 Published by Elsevier Inc.1. Introduction
In a recent commentary on diagnostic and classification
problems of neuroendocrine (NE) tumors [1], several frequently
asked questions (FAQ) were discussed, and some tentative
answers offered to specific topics. Among them, the issue of
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ttp://dx.doi.org/10.1016/j.humpath.2013.03.016briefly addressed (FAQ #4) with regard to their occurrence in
several extrapulmonary organs, as either small cell carcinomas
(SCC) or large cell NECs (LCNEC), apparently very similar to
their well-known respective pulmonary counterparts [2,3]. In
the literature, the occurrence of extrapulmonary poorly
differentiated NECs (EPNEC) has been reported in single
case reports (see review [4]), and only recently were relatively
large series collected and analyzed from both clinical and
pathological perspectives [5].However, the pathological aspects
as well as the therapeutic strategies of EPNEC still seem rather
heterogeneous in the literature, and the present review collects
the available diagnostic and therapeutic information on this
tumor group, highlighting crucial issues and possible solutions.
2 M. Volante et al.2. Relevant issues and possible solutions
2.1. Issue 0: organ distribution and incidence
EPNECs are defined as malignant epithelial tumors
having a totally or predominant NE differentiated cell
population and high-grade features. They are rare or
extremely rare outside the lung and can develop in virtually
any location. Relatively large series were reported in the
gastroenteropancreatic (GEP) area, including the esophagus
[6], stomach [7,8], colon and rectum [9], and pancreas [10].
In addition, EPNECs of the small or large type were
investigated in the prostate [11,12], bladder [13] and uterine
cervix [14,15]. Overall, EPNECs account for no more than
3% of all malignancies in individual anatomical sites.
NECs have also been described in the skin for more than
40 years, under the generic term of Merkel cell carcinoma.
Although the morphology of classical small cell forms is not
different from that of small cell lung cancer, Merkel cell
carcinoma has heterogeneous morphological and molecular
features, as well as variable and peculiar clinical behavior
and therapeutic implications. For these reasons it has been
excluded from the present review.2.2. Issue 1
2.2.1. Problem: How to label these tumors?
2.2.1.1. Solution: Use the general term EPNEC; quote
synonyms. A relatively long list of different terms are
currently used to label these tumors. They refer either to cell
size (extrapulmonary small or LCNECs), to tumor grade
(high-grade NEC, G3) or to loss of differentiation (poorly
differentiated NE/endocrine carcinomas). In addition, the
occurrence of combined small and large cell NEC has been
reported not only in the lung but also in some other locations
(stomach, gallbladder, bladder, etc), although this distinction
is not considered of clinical or prognostic relevance in these
organs (including the lung) [5]. The terminology used for
such tumor type(s) is itself heterogeneous, being only
partially derived by their largely more common pulmonary
counterpart. In fact, for LCNEC in extrapulmonary organs,
the original terminology proposed by Travis and coworkers
for the corresponding lung tumors has often been adopted [3],
whereas when series of pure NECs or mixed/combined
carcinomas are investigated in the stomach or colon rectum or
bladder, the nomenclature is more confused and either SCC orFig. A and B, A biopsy specimen of a small cell NEC of the stom
respectively). C-F, A case of LCNEC of the rectum, deeply invasive (
prominent nucleoli (D), typical dot-like patterned chromogranin A express
E and F, immunoperoxidase; original magnification: C, ×100; D and F, ×4
distinct tumor cell populations (G) with chromogranin A positivity restri
micrometastasis from the adenocarcinomatous component (I) (G and I,
×100; I, ×400). J, A biopsy specimen of a case of small cell carcinom
magnification ×200). K, A case of LCNEC of the renal pelvis (H&E; orpoorly differentiated NEC terms are used, often interchange-
ably. In our view, this is not appropriate, since pure SCC
generally do not differ from their classical pulmonary
counterpart (oat cell type), but all other variants including
intermediate cell type (a definition included in previous
classifications), LCNEC and combined NE/non-NECs actu-
ally display more complex morphological features, which
cannot be directly addressed to one histological type.
Referring to the available World Health Organization
(WHO) classifications, the 2010 WHO classification of
tumors of the digestive system restricted the term “NEC”
to poorly differentiated, clinically aggressive neoplasms,
which are graded as G3 by definition [16]. Similar to the
lung, these include small and large cell variants (or a
combination of the two), being relatively common in the
stomach and very rare in the pancreas. By contrast, in
other WHO classification schemes (namely of the
urogenital tract and breast/female genital organs) [17,18]
nomenclature per se is heterogeneous and include general
terms such as NEC not otherwise specified or consider
SCC type, only.
For practical purposes, in analogy to what is proposed in
the GEP system, the nomenclature of EPNEC is advisable,
with a subspecification of either small or large cell types.
Such uncommitted terminology would allow to compare the
pathological features and the real prevalence of EPNEC, as
well as to address the issue of their most appropriate
therapeutic strategy.2.3. Issue 2
2.3.1. Problem: Differential diagnosis of small and
large cell NEC
2.3.1.1. Solution: Identify architectural patterns, cytolo-
gical features, and appropriate immunophenotype. EP-
NEC of the classical small cell type has uniform
morphological features, irrespective of the organ in which
they develop, overall similar to those of the pulmonary
counterpart (Fig.). Conversely, other EPNEC forms, includ-
ing pure LCNEC and combined small and large cell
carcinomas, have peculiar features with differences in
various locations (Table 1).
From a pathological point of view, the distinction
between small and large cell tumors is of relevance for the
purpose of a correct classification of the tumor itself and,
above all, an accurate differential diagnosis from otherach (H&E; original magnification ×200 and ×400 for A and B,
C), composed of large atypical cells with irregular nuclei having
ion (E), and very high Ki-67 proliferation index (F) (C and D, H&E;
00; E, ×200). G-I, A mixed adeno-NEC of the stomach showing two
cted to the NE (large-cell) component (H) and a single lymph node
H&E; H, immunoperoxidase; original magnification: G, ×200; H,
a of the bladder with extensive crushing artifacts (H&E; original
iginal magnification ×200).
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Table 1 Comparison of general characteristic of pulmonary and extrapulmonary (divided into GEP and urogenital tract locations) NECs
Location Relative frequency
as compared to
NETs (carcinoids)
Most prevalent type
(SCC vs LCNEC)
Frequency of mixed
NE and non-NE
features
Etiologic/
risk factors
Precursor lesions
Lung More frequent SCC Very rare Cigarette smoking Unknown
GEP Less frequent LCNEC Frequent Unknown Unknown (possibly divergent
differentiation from adenocarcinoma)
Urogenital
tract
More frequent SCC More than 50%
of cases
Unknown Unknown (possibly divergent
differentiation from carcinoma
subtypes)
4 M. Volante et al.conditions made of either small or large cells in individual
organs, which may be problematic especially in cytology
[19] or tiny biopsy specimens. In practical terms, it was
claimed that the distinction between SCC and LCNEC is an
apparently useless exercise, not only due to the similar
clinical behavior reported above but also because many cases
(indeed probably the majority of them) actually contain
mixed cell populations, all sharing more or less evident NE
features but displaying various cell sizes. In any case, a full
range of options is possible, including pure SCC (former “oat
cell”) cancers on the one side and LCNEC on the other. In
between, various combinations of small and large cell
carcinomas may occur, covering the whole spectrum of cell
sizes and having variable tumor architecture and cytological
features. As a matter of fact, similar to what is observed in
the lung, small cell EPNEC are usually neoplasms with a
diffuse (solid or noncohesive) growth and finely granular
nuclei lacking evident nucleoli. By contrast, large cell
EPNEC present a more structured architecture (solid,
trabecular, or organoid) and frequently large nuclei with
hyperchromatic nucleoli.
The occurrence of EPNEC may also create differential
diagnostic problems with poorly differentiated forms of
their respective nonendocrine carcinomas or other malig-
nancies such as hematological and mesenchymal neo-
plasms. As an example, small cell EPNEC in the bladder
may be easily misdiagnosed as urothelial carcinoma [20],
also because often a combination of these two forms exists
(see also below).
Concerning the differential diagnoses mentioned above,
there are no markers useful to discriminate small cell from
large cell cases. Both display an epithelial immunoprofile,
with wide spectrum cytokeratin expression, which may
occasionally have a paranuclear dot-like distribution,
especially in the case of SCC. Conversely, high-molecular-
weight cytokeratins (types 1, 5, 10, 14 of the Moll’s catalog)
are typically absent in the vast majority of NE differentiated
carcinomas irrespective of the location [21,22]. Among NE
markers, chromogranin A (more often with a focal para-
nuclear dot-like pattern unmasked by heat-induced antigen
retrieval procedures) and synaptophysin are the most reliablemolecules supporting the morphological evaluation, while
neuron-specific enolase (NSE) and CD56 are sensitive but
much less specific. Interestingly, up to 80% of EPNEC
express the thyroid- and lung-specific marker TTF-1, thus
limiting its usefulness in the definition of the primary
location in the cases of NEC of unknown primary origin
[23,24].
An additional relevant challenge for pathologists is the
differential diagnosis between high-grade NECs and well-
differentiated, low-grade NE neoplasms (“carcinoid”). This
is not an obvious exercise in the daily pathology practice,
especially when facing small endoscopic biopsies or needle
aspirates from metastatic sites (eg, liver). In fact, cases of
well-differentiated NE tumors (NETs) made of small cells do
exist as either the result of artifactual cellular size changes
(frequent in small biopsies or cytological specimens) or,
more rarely, as a special small cell variant of such tumors. In
surgical specimens, the diagnosis is generally easy, in the
presence of an organoid or trabecular growth of low-grade
NETs but may not be straightforward in preoperative
specimens. Although not specifically addressed for tumors
in extrapulmonary locations, a study of 7 pulmonary
carcinoid tumors wrongly interpreted as SCCs in the biopsy,
but confirmed as low-grade NETs in the surgical specimen,
showed that Ki-67 index is the most reliable marker for a
differential diagnosis of high-grade carcinomas from carci-
noid tumors [25].
In addition, cases exist of well-differentiated NETs
having a borderline number of mitoses and/or extensive
necrosis, which may induce the suspicion of an EPNEC.
The usual approach is to perform an accurate mitotic
count usefully supported by a Ki-67 immunostaining.
However, with special reference to the GEP system, a
grey zone (not well clarified by the WHO classification)
exists in terms of proliferation between NEC (all Grade 3)
and rare NETs showing a well-differentiated morphology
but a Ki-67 labeling index higher than 20% (thus by
definition G3, too). In this latter case, an additional useful
method might be to consider the pattern and intensity of
reactivity for chromogranin A, which is generally focal
and/or located paranuclear in a dot-like fashion in high-
5Extrapulmonary neuroendocrine small and large cell carcinomagrade EPNECs, while stronger and uniformly cytoplasmic
in well-differentiated NETs.
2.4. Issue 3
2.4.1. Problem: What is the real role of Ki-67 index in
small versus large cell NEC?
2.4.1.1. Solution: Mandatory use of Ki-67 index for
grading GEP NEN, only. As a rule, Ki-67 index is to be
assessed in all GEP NE neoplasms [16] to define tumor
grading, with an accurate manual count rather than with an
“eyeballing” approach [26]. However, Ki-67 evaluation is
not valuable to distinguish small from large cell NECs, and
there are no specific recommendations for Ki-67 investiga-
tion in sites other than the GEP system.
A literature review of the reported Ki-67 values in
EPNEC is summarized in Table 2, based only on published
papers clearly reporting Ki-67 values for small and/or large
cell components in EPNECs. Despite the difficulty of
comparing the various figures obtained by different authors
(also due to different classification criteria for small and
large cells, as well as different counting methods), it seems
that the mean proliferative index of small cell patterned
NECs is slightly higher than that of morphologically proven
LCNECs originated from pancreas, larynx, bile ducts,
gastrointestinal tract, parotid, and urogenital tract (70.9%
versus 62%).Table 2 Review of reported small versus large cell EPNECs with Ki
Ref No. of cases Location
Nagao et al 2000 [27] 2 Parotid
Papotti et al 2000 [28] 2 Gallbladde
Crafa et al 2003 [29] 1 Rectum
Soriano et al 2004 [30] 10 Bladder
Sugawara et al 2004 [31] 1 Ampulla o
Fernandez-Figueras et al 2005 [32] 23 Bladder/lu
Stachs et al 2005 [33] 1 Endometri
Lee et al 2009 [34] 1 Bladder
Miyamoto et al 2006 [35] 1 Rectum
Malhotra et al 2008 [36] 1 Liver
Kozyrakis et al 2009 [37] 1 Bladder
Yamaguchi et al 2009 [38] 1 Breast
Lewis et al 2010 [39] 10 Larynx
Righi et al 2010 [40] 11 Breast
Stojsic et al 2010 [41] 1 Ampulla o
Terada 2010 [42] 1 Endometri
Terada 2011 [43] 1 Esophagus
Albisinni et al 2012 [44] 1 Prostate
Benkel et al2012 [45] 1 Gallbladde
Jianu et al 2012 [46] 1 Stomach
Samad et al 2012 [47] 1 Bile ducts
Yachida et al 2012 [10] 19 Pancreas
Yamamoto et al h2012 [48] 1 Pancreas
Mean values 93 cases2.5. Issue 4
2.5.1. Problem: How to classify EPNEC combined with
adeno-, squamous, or urothelial carcinoma?
2.5.1.1. Solution: Heterogeneous criteria exist in different
organs; favor morphological parameters and appropriate
immunophenotypes. One of the most challenging (and
also difficult to identify and treat) situation is the
combination of NEC with a more or less well-represented
non-NE component. Such component may be totally
separated from the EPNEC (collision tumor) but more
often is intermingled with the NEC population and indeed
may not be readily apparent. This is especially true in cases
of EPNEC combined with poorly differentiated non-NE
components (for example basaloid squamous carcinoma of
the uterine cervix or undifferentiated urothelial carcinoma).
For the pathological diagnosis of such cases, a first clue is
to identify the NE cell population as such, and then the
relative proportions of the exocrine and endocrine compo-
nents are to be determined [49].
In the GEP area, this step is mandatory for the purpose of
identifying so-called MANECs (mixed adeno-NEC), being
at least 30% of each component required for rendering such a
diagnosis in any given mixed tumor. In the stomach, mixed
tumors follow a behavior intermediate between pure LCNEC
(the most aggressive subgroup) and conventional gastric
adenocarcinoma [7]. In the colon and rectum, the extent of-67 index evaluation
Ki-67 index (%) in different components
Small cell Large cell
- 55.3 (53.4-57.1)
r - 60.5 (50-71)
- 50
33 (15-70) -
f Vater 54 -
ng 64.7 -
um 50 -
- 40
- 87.8
90 -
70 -
85 -
- 64.2 (10-100)
58 (40-75) -
f Vater - 41
um - 80
100 -
100 -
r 70 -
- 90
- 70
67 (n = 9) (55.1-85.8) 43.4 (n = 10) (20-68.4)
80 -
70.9 62
6 M. Volante et al.the NE component (within the 30% rule) is not a predictor of
behavior, and even a minor high-grade NE cell population
was found able to metastasize [50]. In such location, the
prognosis was comparable between MANEC (mixed adeno-
neuroendocrine carcinoma) and NEC, with a better prognosis
in cases whose NE component was made of large cells [9].
Very few cases of concurrent adenocarcinoma and NEC in
the hepatobiliary organ were reported [51].
In other locations, there are either different diagnostic
rules or none. NE breast carcinoma is one of the several
variants of this neoplasm and is defined as a tumor having
NE morphological features necessarily associated with the
immunohistochemical expression of NE markers in at least
50% of the tumor [18]. Such tumor type may display variable
morphological patterns, including high-grade NEC of the
large or small cell type. These latter are generally pure forms
of primary breast EPNECs and therefore the NE cell
population largely exceeds the required 50% and reaches
90% to 100%. The other NE breast carcinomas are rather
classical ductal or lobular carcinomas combined with a
prominent (N50%) NE cell component having mucinous,
trabecular, alveolar, or solid patterns, which morphologically
have little to do with the currently discussed small or large
cell NE cancers [40].
In the thymus, the definition of combined exocrine-NEC,
as part of thymic carcinoma (type C), is rather generic, being
restricted to the recognition of “two distinct areas, each
corresponding to one of the histological types, including
NEC” [52].
In the urogenital tract, combined carcinomas are as
common as pure forms of EPNEC. In the prostate, EPNECs
occur as either pure SCC (57%) or combined with an
adenocarcinoma having a high (≥8) Gleason score,
according to the largest published series of 95 cases [12].
In the bladder, no criteria are mentioned for the definition of
mixed NEC: SCCs combined with urothelial, squamous, or
adenocarcinoma occur more frequently (70%) than pure
forms [53], and the trend is similar for the even rarer
LCNEC [54].
Similarly, in the ovary and in the uterine cervix there are
no specific rules. In the latter, the NE component in an
otherwise squamous cell carcinoma has been described to
range from focal (17%) to half a tumor, but NE differenti-
ation was associated with an adverse prognosis irrespective
of the extension [55].
2.6. Issue 5
2.6.1. Problem: Does molecular signature keep separate
small and large cell EPNEC?
2.6.1.1. Solution: There are insufficient published data on
this issue. Published genetic data are mostly dealing with
mixed/combined exocrine-NECs, while separate analyses of
large and small cell components within the same NET or
comparison of genetic profiles in SCC versus LCNEC are
lacking or are restricted to the pulmonary location, where a
genetic similarity between SCC and LCNEC componentswithin individual tumors is seen [56]. On the contrary,
different genetic abnormalities in chromosomes 3p and 5q
were found between pulmonary small and LCNECs, with
only some overlapping features [57]. Moreover, data on a
large series of lung SCC and LCNEC demonstrated that gene
expression profiles are heterogeneous in the 2 forms and
cluster analysis was unable to separate the two entities, but
rather identified clinically distinctive subgroups [58].
In extrapulmonary locations, only a single recent study
[10] analyzed 19 pancreatic NECs (9 small and 10 large
cells), as well as 11 well differentiated NETs, for alterations
of KRAS, CDKN2A/p16, P53, SMAD4/DPC4, DAXX,
ATRX, PTEN, Bcl2, and RB1 genes. Small and large cell
NECs had genetically similar profiles but distinct from those
observed in well-differentiated NETs. Other studies are
restricted to single case reports, such as esophageal [43] and
endometrial [42] EPNECs, that were investigated for KIT
and PDGFRA gene status, finding no mutations. Finally,
some cytogenetic differences were reported between primary
pulmonary and extrapulmonary SCC [59]. Overall, the
current knowledge does not support or disprove a molecular
separation of small and large cell pulmonary nor extra-
pulmonary NECs.
2.7. Issue 6
2.7.1. Problem: Any clinical meaning of distinguishing
small and large cell NEC (in terms of behavior or
therapeutic strategy)?
2.7.1.1. Solution: Yes, for differential diagnosis purposes.
Probably yes for tuning chemotherapy protocols; in the
future, personalized treatments are expected. Having
defined the criteria for taking small cell apart from large
cell carcinoma forms, the next question arises if this really
matters. The reason for this question relies on the comparable
overall survival for surgically resected pulmonary SCC and
LCNEC, with figures of approximately 35% and 40%,
respectively [60]. In this scenario, however, relatively recent
reports seem to indicate a unique response rate of EPNEC to
chemotherapy protocols conventionally used for pulmonary
SCC [61].
Running through therapy-oriented studies on EPNEC
available in the literature, it can be concluded that the
treatment of EPNEC of the small cell type does not differ
from the pulmonary counterpart [62–64] with response rates
and global prognosis in general overlapping with those
reported for lung SCC, even though some authors reported
poorer results [65]. Since LCNECs of the lung, at least in
their advanced stage, are also treated similarly to SCC [66],
the whole spectrum of EPNEC generally undergoes the same
chemotherapy approach. Indeed, some reports indicate that
despite that the chemotherapy protocols are quite similar,
response to therapy is different and the stability of disease
after completion of chemotherapy may follow a different
course [61,63,67].
The first report on EPNEC therapy goes back to 1991
when Moertel and coworkers [68] firstly proposed platinum-
7Extrapulmonary neuroendocrine small and large cell carcinomaetoposide regimens in NEC and identified a 67% response
rate with a median survival of 19 months. These apparently
excellent results were subsequently confirmed in 41 EPNEC
patients who displayed a 42% response rate and a 15-month
median survival [69]. Nowadays, according to the North
American Neuroendocrine Tumor guidelines [64], first-line
systemic chemotherapy with a platinum agent (cisplatin or
carboplatin) and etoposide is recommended for most EPNEC
patients with metastatic-stage disease; however, response
durations are often short. Sequential or concurrent chemo-
radiation is recommended for patients with locoregional
disease [70].
Unfortunately, more recent studies reported less favorable
clinical results. In 21 unresectable or recurrent hepatobiliary
and pancreatic EPNECs, combination chemotherapy with
cisplatin and etoposide provided a 14% response rate and a
median overall survival of 5.8 months [71]. Comparing the
efficacy of a platinum-containing regimen in 41 advanced
EPNECs with that of SCC of the lung, the response rates
were much worse in the former (31% versus 78%) [61]. This
remarkable discrepancy might be due to the different nature
of the 2 tumors (classical pulmonary SCCs are highly
chemosensitive undifferentiated neoplasm, while EPNEC
include more heterogeneous cancer subtypes), or to the
anatomical location of the tumors, as partially confirmed by
the worse response of hepatobiliary and pancreatic NECs
(12% versus 57% for the other locations).
In a review of over 500 reported NETs with an unknown
primary, despite the heterogeneity in terms of histology,
grade, anatomic site, and tumor biology, it was found that
most cases were managed with platinum-based regimens.
The 294 patients with follow-up information had a median
survival of 15.5 months, comparable to that reported for
high-grade pulmonary and extrapulmonary NECs, even if
the identification of the primary location or tumor type (small
versus large cell type) was missing [72].
In a large series of 179 uterine cervix SCC, a mean
progression-free survival of 16 months and a cancer-specific
survival of 25 months were observed after a treatment based
on platinum and etoposide and concurrent chemo- and
radiation therapy further improved survival (up to 75%).
Mixed small cell and squamous cell carcinoma patterns were
recognized in 47 of 179 cases, but this feature did not affect
response rates [15].
2.8. Issue 7
2.8.1. Problem: Any predictive factor of response to
therapy in EPNEC?
2.8.1.1. Solution: Assess proliferation index in all cases;
in the future, personalized treatments are expected. In the
large series of GEP NEC analyzed in the NORDIC study [63]
a negative prognostic role of performance status, colorectal
primary, elevated platelet, and lactose dehydrogenase (LDH)
levels was observed. Proliferation index differed in terms of
impact on survival and response to chemotherapy. In fact, it
was found that Ki-67 index at a cut-off of N55%was a positivepredictor of response to platinum-based regimens (15% versus
42% comparing b55% versus N55% Ki-67, respectively), but
patients with Ki-67 b55% had a significantly longer survival
compared with patients with higher Ki-67 levels (14 versus 10
months). Unfortunately, in this study no morphological
review of the cases was performed, thus leaving the question
open as to the prevalent histological type of tumors associated
with a better response.
With regard to molecular targets of chemotherapeutic
agents, it has been reported that pulmonary SCC are not
responsive to pemetrexed and in general to antifolate drugs
[73]. This was supported by the observation that high-grade
NEC of the small and large cell type and of both pulmonary
and GEP origin express high levels of thymidylate synthase,
the most important target molecule of antifolates [74], thus
supporting the usefulness of assessing the intratumoral
expression levels of known targets, to better define the
therapeutic strategy and/or predict response to different
agents. Recent data are emerging with regard to the
activation of intracellular signaling pathways as possible
targets of specific treatments. A high phospho–mammalian
target of rapamycin expression was reported in 9 poorly
differentiated (large cell type) GEP NEC [75], suggesting
that mammalian target of rapamycin could be explored as a
possible therapeutic target in this subtype, as already well
known for low-grade NETs.3. Conclusions
i. based on both clinical and pathological findings and
from a practical point of view, a common terminology
is advisable for pure extrapulmonary high-grade
NECs, using the acronym EPNEC and a subsequent
distinction into small and large cell subtypes;
ii. similar to the lung, small and large cell EPNECs differ
histologically by cell size, architecture, and nuclear
features, although morphologically intermediate cases
exist and the general genetic background, as well as the
clinical behavior, are similar in the 2 forms;
iii. recognition of mixed NE/non-NE forms in extra-
pulmonary locations is based on morphology and
appropriate immunophenotype; due to its relatively
high frequency, it should be excluded by extensive
sampling, and the relative proportions on NE and non-
NE components should be reported in any case to
better understand the impact on clinical behavior and
response to treatment(s);
iv. immunohistochemistry is useful to distinguish EPNEC
from poorly differentiated non-NECs (using NE
markers) and from well-differentiated NETs (using
Ki-67, especially in small tissue fragments/cytological
samples), but not to differentiate small and large cell
EPNEC forms;
v. the pathogenesis of EPNEC is unclear and possibly
different from that of pulmonary NECs;
8 M. Volante et al.vi. platinum-based chemotherapy represents the most
commonly used therapeutic approach in EPNEC
(both small and large cell types), based on similarity
between EPNEC and pulmonary SCC. However, some
increasing evidence seem to indicate that response to
therapy and prognosis are different between pulmo-
nary and extrapulmonary NEC and possibly between
EPNEC of the small and large cell types.
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